- Home
- FLYE vs CDIO Comparison
FLYE vs CDIO Comparison
Compare FLYE & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- CDIO
- Stock Information
- Founded
- FLYE 2018
- CDIO 2017
- Country
- FLYE United States
- CDIO United States
- Employees
- FLYE N/A
- CDIO N/A
- Industry
- FLYE Aerospace
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- FLYE Industrials
- CDIO Health Care
- Exchange
- FLYE Nasdaq
- CDIO Nasdaq
- Market Cap
- FLYE 10.7M
- CDIO 12.3M
- IPO Year
- FLYE 2024
- CDIO N/A
- Fundamental
- Price
- FLYE $0.41
- CDIO $0.90
- Analyst Decision
- FLYE
- CDIO Buy
- Analyst Count
- FLYE 0
- CDIO 1
- Target Price
- FLYE N/A
- CDIO $2.00
- AVG Volume (30 Days)
- FLYE 193.5K
- CDIO 12.3M
- Earning Date
- FLYE 02-10-2025
- CDIO 11-13-2024
- Dividend Yield
- FLYE N/A
- CDIO N/A
- EPS Growth
- FLYE N/A
- CDIO N/A
- EPS
- FLYE N/A
- CDIO N/A
- Revenue
- FLYE $30,297,313.00
- CDIO $35,688.00
- Revenue This Year
- FLYE N/A
- CDIO $2,093.61
- Revenue Next Year
- FLYE N/A
- CDIO $43.05
- P/E Ratio
- FLYE N/A
- CDIO N/A
- Revenue Growth
- FLYE 14.77
- CDIO 180.90
- 52 Week Low
- FLYE $0.40
- CDIO $0.19
- 52 Week High
- FLYE $7.62
- CDIO $3.56
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- CDIO 58.19
- Support Level
- FLYE N/A
- CDIO $0.99
- Resistance Level
- FLYE N/A
- CDIO $1.77
- Average True Range (ATR)
- FLYE 0.00
- CDIO 0.27
- MACD
- FLYE 0.00
- CDIO 0.04
- Stochastic Oscillator
- FLYE 0.00
- CDIO 41.73
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.